200 related articles for article (PubMed ID: 33545804)
21. Niraparib: First Global Approval.
Scott LJ
Drugs; 2017 Jun; 77(9):1029-1034. PubMed ID: 28474297
[TBL] [Abstract][Full Text] [Related]
22. Human mass balance study and metabolite profiling of
van Andel L; Zhang Z; Lu S; Kansra V; Agarwal S; Hughes L; Tibben MM; Gebretensae A; Lucas L; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH
Invest New Drugs; 2017 Dec; 35(6):751-765. PubMed ID: 28303528
[TBL] [Abstract][Full Text] [Related]
23. Niraparib Slows Ovarian Cancer Progression.
Cancer Discov; 2016 Dec; 6(12):OF2. PubMed ID: 27810860
[TBL] [Abstract][Full Text] [Related]
24. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
Moore KN; Mirza MR; Matulonis UA
Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
[TBL] [Abstract][Full Text] [Related]
25. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
[TBL] [Abstract][Full Text] [Related]
26. Interstitial lung disease caused by niraparib in ovarian cancer patient: a case report and literature review.
Shono M; Murakami K; Ohta M; Nakai H; Matsumura N
Jpn J Clin Oncol; 2024 Mar; 54(3):352-356. PubMed ID: 38109478
[TBL] [Abstract][Full Text] [Related]
27. Niraparib in ovarian cancer: results to date and clinical potential.
Caruso D; Papa A; Tomao S; Vici P; Panici PB; Tomao F
Ther Adv Med Oncol; 2017 Sep; 9(9):579-588. PubMed ID: 29081841
[TBL] [Abstract][Full Text] [Related]
28. Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic
Tao M; Cheng J; Wu X
Onco Targets Ther; 2020; 13():12979-12986. PubMed ID: 33376347
[TBL] [Abstract][Full Text] [Related]
29. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
Matulonis UA; Walder L; Nøttrup TJ; Bessette P; Mahner S; Gil-Martin M; Kalbacher E; Ledermann JA; Wenham RM; Woie K; Lau S; Marmé F; Casado Herraez A; Hardy-Bessard AC; Banerjee S; Lindahl G; Benigno B; Buscema J; Travers K; Guy H; Mirza MR
J Clin Oncol; 2019 Dec; 37(34):3183-3191. PubMed ID: 31518175
[TBL] [Abstract][Full Text] [Related]
30. Successful Treatment of a Patient With Brain Metastasis From Ovarian Cancer With BRCA Wild Type Using Niraparib: A Case Report and Review of the Literature.
Zhang Z; Xu M; Sakandar A; Du X; He H; He W; Li D; Wen Q
Front Oncol; 2022; 12():873198. PubMed ID: 35574424
[TBL] [Abstract][Full Text] [Related]
31. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
Del Campo JM; Matulonis UA; Malander S; Provencher D; Mahner S; Follana P; Waters J; Berek JS; Woie K; Oza AM; Canzler U; Gil-Martin M; Lesoin A; Monk BJ; Lund B; Gilbert L; Wenham RM; Benigno B; Arora S; Hazard SJ; Mirza MR
J Clin Oncol; 2019 Nov; 37(32):2968-2973. PubMed ID: 31173551
[TBL] [Abstract][Full Text] [Related]
32. Rapid and temporary improvement of depression and anxiety observed following niraparib administration: a case report.
Jewett BE; Miller MN; Ligon LA; Carter Z; Mohammad I; Ordway GA
BMC Psychiatry; 2020 Apr; 20(1):171. PubMed ID: 32295563
[TBL] [Abstract][Full Text] [Related]
33. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
Wang Z; Sun K; Xiao Y; Feng B; Mikule K; Ma X; Feng N; Vellano CP; Federico L; Marszalek JR; Mills GB; Hanke J; Ramaswamy S; Wang J
Sci Rep; 2019 Feb; 9(1):1853. PubMed ID: 30755715
[TBL] [Abstract][Full Text] [Related]
34. Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study.
Gallagher JR; Heap KJ; Carroll S; Travers K; Harrow B; Westin SN
Future Oncol; 2019 Dec; 15(36):4197-4206. PubMed ID: 31707856
[No Abstract] [Full Text] [Related]
35. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
Penn CA; Wong MS; Walsh CS
JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
[TBL] [Abstract][Full Text] [Related]
36. Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Moore K; Chan JK; Secord AA; Patel MR; Callahan T; Guo W; Zhang ZY
Cancer Chemother Pharmacol; 2019 Apr; 83(4):717-726. PubMed ID: 30680521
[TBL] [Abstract][Full Text] [Related]
37. The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer.
Moore K; Zhang ZY; Agarwal S; Burris H; Patel MR; Kansra V
Cancer Chemother Pharmacol; 2018 Mar; 81(3):497-503. PubMed ID: 29322231
[TBL] [Abstract][Full Text] [Related]
38. Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts.
Póti Á; Berta K; Xiao Y; Pipek O; Klus GT; Ried T; Csabai I; Wilcoxen K; Mikule K; Szallasi Z; Szüts D
Br J Cancer; 2018 Nov; 119(11):1392-1400. PubMed ID: 30425352
[TBL] [Abstract][Full Text] [Related]
39. Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a
van Andel L; Rosing H; Zhang Z; Hughes L; Kansra V; Sanghvi M; Tibben MM; Gebretensae A; Schellens JHM; Beijnen JH
Cancer Chemother Pharmacol; 2018 Jan; 81(1):39-46. PubMed ID: 29043410
[TBL] [Abstract][Full Text] [Related]
40. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
